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Background
Since the discovery of the cystic fibrosis (CF) gene in 1989,
attempts have been made to develop a new therapeutic
approach by targeting the underlying CFTR protein defect.
Ivacaftor (Kalydeco®, Vertex Pharmaceuticals) is the first
of a new class of drugs known as CFTR protein potentia-
tors. This drug is functional in “CFTR gating” or type III
mutations, in which a dysfunctional CFTR protein is pre-
sent at the apical membrane. Ivacaftor facilitates improved
chloride transport by increasing the opening time of the
CFTR channel 1. Research has shown that treatment with
ivacaftor can significantly improve lung function by about
10% [1]. Adverse events of ivacaftor include upper respira-
tory tract infections, nasal congestion and headaches [2].
Case report
In our case report we illustrate a positive effect of ivacaftor
on the sinonasal pathology in a 17 year old patient with
CF. Her CF genotype showed a heterozygous deltaF508/
S1251N mutation, in which the S1251N mutation is a type
III mutation and can therefore be influenced by ivacaftor.
In addition to her pulmonary symptoms she chronically
suffered from headaches and nasal obstruction, most likely
caused by chronic rhinosinusitis. During these complaints
two CT-sinuses were performed (fig. 1A and 1B), showing
opacification of all paranasal sinuses. Despite accurate
treatment of the rhinosinusitis, with nasal irrigations, nasal
steroids complaints persisted. After 5 months of ivacaftor
use, a new CT-sinus (fig. 1C) showed complete resolution
of the opacification of the paranasal sinuses and a decrease
in symptoms of sinonasal disease. This positive effect of
ivacaftor on sinonasal pathology seems promising, there-
fore more research is needed to evaluate the effect of
ivacaftor on the upper airways in CF.
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